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Abstract 
Objectives 
Kawasaki disease (KD) is an increasingly common vasculitis with risk of coronary artery aneurysms (CAA). The 
last UK survey was in 1990 whereas current epidemiology, treatment patterns, and complication rates are 
unknown, and the aim of this study was to address that knowledge gap. 
Methods 
A British Paediatric Surveillance Unit (BPSU) survey in the UK and Ireland from 01.01.2013 to 28.02.2015 
ascertained demographics, ethnicity, seasonal incidence, treatment, and complication rates.  
Results 
553 cases were notified: 389 had complete KD; 46 had atypical KD; and 116 had incomplete KD, two diagnosed 
at post-mortem with incidence 4.55/100,000 children under 5 years, male: female ratio 1.5:1, median age 2.7 
years (2.5 months-15 years). Presentation was highest in January and in rural areas. Most were White (64%); 
Chinese and Japanese Asians were over-represented as were Black African or African mixed-race children. 94% 
received intravenous immunoglobulin (IVIG). The overall CAA rate was 19%, and all-cardiac complications 
affected 28%. Those with CAA received IVIG later than in those without (median 10 days vs 7 days). Those under 
1 year had fewer symptoms, but highest CAA rate (39%). Overall 8/512 cases (1.6%) had giant CAA; and 4/86 
cases (5%) under 1 year of age developed giant CAA. Mortality from KD was 0.36%. 
Conclusions 
The UK and Ireland incidence of KD has increased and is more frequently seen in winter and rural areas. Delayed 
IVIG treatment is associated with CAA suggesting earlier and adjunctive primary treatment might reduce 
complications to prevent CAA, particularly in the very young.  
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BACKGROUND 
Kawasaki Disease (KD) is a self-limiting medium vessel vasculitis of unknown aetiology that typically presents in 
children and adolescents with fever and muco-cutaneous changes. If left untreated, 15-25% of children will develop 
coronary artery aneurysms (CAA); 2%–3% of untreated cases die as a result of coronary vasculitis causing myocardial 
ischaemia, sometimes many years later 1. The incidence of KD varies from 264 per 100,000 children under 5 years 
in Japan, to about 5-8 per 100,000 in England 2 3. The high rate in North East Asians, which persists after migration 
to countries with low incidence 4, is strong evidence for a genetic factor and there is clear evidence from genome wide 
association studies of an important role for genetic variants in determining susceptibility. The aetiology of KD is 
unknown, but seasonal variation, occurrence of epidemics and association with wind patterns would be compatible 
with an infectious or toxic trigger 5 6. 
 
KD is the commonest cause of acquired heart disease in children in the UK and USA 7 8. Prompt diagnosis is 
essential to minimize complications. Intravenous immunoglobulin (IVIG) has formed the mainstay of primary 
treatment following publication of a seminal clinical trial in the 1980s 9. However, IVIG-resistance occurs in up to 
20-40% of unselected cases and is associated with increased coronary complication rates 1 10. Recent studies 
and meta analyses of all published studies have suggested that addition of corticosteroids to IVIG reduces the 
risk of CAA, particularly in high risk patients 1 10 11. However, there is currently no reliable method to predict which 
patients are at risk of CAA and thus require additional treatment, as scoring systems that predict IVIG non-
response in Japan have not been reliable in studies in UK and North America. 
 
The last comprehensive epidemiological study of KD in the UK was undertaken by the British Paediatric 
Surveillance unit (BPSU) in 1990 12. This revealed an incidence of 3.4/100,000 children under 5 years from 
January 1st to 31st December 1990; and a higher than expected coronary complication rate of 29% in those 
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children who had received IVIG, comparable to those patients who did not receive IVIG. More recent 
epidemiological studies noted a higher UK incidence of 8.39-9.1/100 000 children under the age of 5 3 8, but both 
were limited by indirect retrospective epidemiological methodologies, and thus may not be accurate. Moreover, 
24% of children with KD are older than five years 13 14 15, but accurate UK epidemiological data are lacking in this 
age group.   
 
The incidence of KD has been reported to be increasing in many countries. Furthermore, the population 
demographics are changing, and there is therefore a need for updated information on KD in the UK 1 16 17. The 
purpose of this study was to establish the current incidence of KD in the UK, noting the seasonal variation; to assess 
complication rates and the factors influencing these; and to shape future management practice based on these data 
(Panel 1). Areas of particular interest included the potential influence of ethnicity, urbanisation, and disease outcomes 
in the light of recently updated clinical guidance regarding the use of corticosteroids for KD 1.  
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Panel 1: Summary of Kawasaki disease BPSU research questions  
METHODOLOGY 
The study used BPSU methodology for the epidemiological research surveillance, similar to the 1990 BPSU KD 
survey 12. Each month all paediatricians and paediatric cardiologists (list available from the Royal College of 
Paediatrics and Child Health and the British Congenital Cardiac Association) were contacted by email to report if 
they had seen a case of KD. If notified, the BPSU would then make the research team aware and a questionnaire 
was posted. This surveillance methodology provided an active, real-time quantitative portrait of KD in the defined 
population. All of the UK and Ireland were included in the study. Also included were the Channel Islands and Isle 
of Man. Incidence was calculated by applying the most recent resident population data from the 2011-2015 
Census of Population 18 and their equivalents from Ireland 19 
 
Panel 2 KD Case definition  
Incidence: 
• What are the demographics (sex, age, ethnicity, area of residence) of those diagnosed with Kawasaki disease (KD) 
in the UK and Ireland less than 16 years old?  
• Has the incidence changed since the last survey in 1990? 
Clinical Presentation and cardiac complications: 
• How does KD first present, and what is the interval between first presentation and diagnosis?  
• What is the frequency and nature of cardiac complications detected using echocardiography within 30 days of 
developing KD?  
Clinical Management: 
• What acute treatment is being given to patients during their initial hospital presentation with KD?  
• Are treatments other than aspirin and intravenous immunoglobulin being used, and if so, has this impacted on 
outcome?  
 
Other Outcomes: 
• What is the frequency of non-cardiac complications within 30 days following KD? 
• How are patients with KD being followed up within the UK and Ireland?  
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Any infant or child up to the age of 16 years presenting for the first time in the UK or Ireland with fever of 5 or more 
days duration plus 4 of the following (complete KD), or plus any 3 of the following (incomplete KD) or plus 2 or 3 of 
the following with coronary artery changes (atypical KD): 
 
1. Conjunctivitis   Bilateral, bulbar, non-suppurative 
2. Lymphadenopathy   Cervical > 1.5cm 
3. Rash    Widespread, polymorphous. Not vesicular.  
4. Lips and mucosa  Red cracked lips, ‘strawberry tongue’, erythematous oral cavity  
5. Changes of extremities Erythema, oedema of palms and soles initially, later peeling of skin  
 
Inclusion criteria 
In the first year, the protocol requested the reporting of only Complete KD cases, but in the second year all cases of 
KD (i.e. including atypical and incomplete KD as per the aforementioned definitions) were included. Where the 
interpretation of clinical features was uncertain, expert panel review (RT, RMW, AR, JT, DS, PB) of the case was 
undertaken to ascertain by consensus (defined as 100% agreement among experts) if the diagnostic criteria for KD 
had been fulfilled, and if so how to classify the subtype of KD (complete, atypical, or incomplete) for inclusion in the 
study.  
 
Exclusion criteria 
Exclusion criteria were patients older than 16 years; outside the pre-defined study period; and those with alternative 
final diagnoses. In addition, for the first year of the study, those with streptococcal infection were excluded, but not in 
the second year of study, since it is now recognized that streptococcal infection (and other infections) may be 
associated triggers for responses resulting in KD 20.  
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Cardiac involvement 
We defined coronary artery aneurysms (CAA) as Z score of ≥ 2.5 internal diameter 21. The Z scores were checked 
or completed, using Cardio Z software, based on the data supplied by Dallaire and Dahdah 22. Those with 
aneurysms were referred to as CAA+ and those without were CAA-. In addition, there were some children with 
bright coronary artery walls, dilated (but non-aneurysmal) coronary arteries, pericardial effusion, or myocarditis. 
These were recorded as cardiac involvement, but not CAA. We recorded the early presence of CAA at diagnosis, 
and also in some cases later echocardiographic data was also presented. Giant aneurysms were defined as 
≥8mm or z score ≥10 23. 
 
DURATION OF THE STUDY 
In accordance with the most recent BPSU methodology, data collection was over a 25-month period, Jan 2013 – 
Feb 2015. All data was collected and retained in accordance with the Data Protection Act 1998. 
 
DATA MANAGEMENT, ANALYSIS AND SECURITY 
As approved by the ethics committee, parental consent was not obtained as the identity of the cases was known 
only to the reporting clinician. Anonymous questionnaires were sent from our study centre after case notification. 
Use of the NHS number and date of birth allowed checks for duplication. Using the first four components of the 
postcode, the population density was estimated by area where each patient lived in the UK and by area in Ireland. 
As most of the data were categorical or not normally distributed, statistical methods based on the Chi-squared 
test were used., Statistical analysis was undertaken at Heriot-Watt University (MD, RS) using SPSS, version 24. 
A p value of <0.05 was considered significant. The distribution of numerical values was summarized as medians 
and ranges; the Wilcoxon-Mann-Whitney test was used for group comparisons of those with or without CAA. A 
complex System Level Security Protocol (SLSP) was utilized and was risk assessed on an annual basis. 
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ETHICAL APPROVAL 
National Research Ethics Committee  11/SW/0310 
NHS Sponsorship   CS/2011/3847 
 
Funding. Kawasaki disease parent support group; and discretionary institutional academic funds from each of the 
authors.  
 
RESULTS 
Between 1 January 2013 and 28 February 2015, 601 reports of KD were received by the BPSU, with 38 duplicates, 
9 other diagnoses and one with no clinical information. Of the remaining 553, there were 389 cases of complete 
KD; 46 atypical cases with fewer than four clinical features but with abnormal echocardiograms; and 116 cases 
of incomplete KD. Two cases were diagnosed retrospectively at post-mortem without any clinical data to allow 
KD-subtype categorisation (Table 1).   
 
Males comprised a significantly greater proportion of the cases, and the proportion of Black and Asian patients 
was increased relative to the expected proportion of these groups in the population (Table 1) 18. There were 
significantly more children under 1 year old with atypical or incomplete KD (45/95; 47%), compared with children 
over 1 year old (102/428; 24%) (Chi-squared = 21.31 p<0.0001).  
 
The annual incidence was estimated using the 257 cases that had been diagnosed between 1 February 2014 and 
31 January 2015, and whose ages were reported since only in the second year were all sub-types of KD reported. 
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The age-specific annual incidences were 4.55/100,000 at age 0-4 years; 1.26/100,000 at 5-9 years, and 
0.08/100,000 at 10-14 years.  
 
Date of diagnosis 
Based on 479 cases reported between1st February 2013 and 31st January 2015, more cases occurred in the 
winter (defined as December – February) and spring (March - May) than in the summer (June - August) and 
autumn (September – November) months (Figure 1) (Chi-squared tests for monthly and seasonal variations were 
significant at  p=0.08). These results controlled for length of month and confirmed the appreciable peaks in 
January in both ‘all’ and ‘complete’ cases. 
 
Time to first point of clinical contact and diagnosis 
443 (80%) children saw a general practitioner (GP) at median (range) 2 (0-27) days from the first onset of 
symptoms. The time from first GP consultation to hospital admission was 1 (0-32) days; time from disease onset 
to formal diagnosis was 7 (0-36) days; and time to diagnosis following admission to hospital was 1 (0-25) days, 
with 50 cases being diagnosed on day of admission.  
 
We used the first four components of the postcode of patients in the UK to assign cases as resident in Urban or 
rural areas and compared the proportion of cases occurring in rural or urban areas. Relative to the population 
density we found significantly more cases occurring in rural areas (applying a non-linear cubic regression offered 
best fit with R2 = 0.867, F=30.290, p<0.005) (Figure 2).  
 
CLINICAL FEATURES 
Coronary artery status 
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The results of the initial echocardiograms were available for 523/553 children. There were 11 children in whom 
the weights and Z scores were missing, so these have been omitted from analysis. Overall, 123/512 (24%) had 
abnormal coronary Z score (Z score >2) at echocardiography within 30 days of diagnosis. Of these, 95/512 had 
coronary Z score ≥ 2.5, thus the overall CAA rate within 30 days of diagnosis was 19%.  
In 25 children, there was a pericardial effusion recorded, and in 7 there was either valve regurgitation or depressed 
ventricular function. Taking these into account, the all-cardiac complication rate (coronary Z>2, or any other 
cardiac complication) was 28% within 30 days of diagnosis (Table 2). It is of note that a much higher proportion 
of children under the age of 1 year had CAA+ (39%) compared with those over the age of 1 (13%, p<0.01). 
Overall, 8/512 cases (1.6%) developed giant CAA, and 4/86 cases (5%) under 1 year of age had giant CAA. 
 
Variables associated with coronary artery aneurysms 
We reviewed the association of CAA status with features highlighted in previous publications (Table 3) to 
determine whether there were any associations with CAA 24 25. In addition, we explored if there were any 
differences in coronary outcomes between 2013 and 2014, which may have been influenced by the publication 
of a new UK clinical guideline paper at the end of 2013 1. In 28 cases, we did not know the coronary artery status; 
and in both of the post mortem cases there were coronary artery aneurysms.  
 
The presence of fever plus four diagnostic features of KD at the time of diagnosis (complete KD) was associated 
with a lower rate of coronary artery involvement. Younger age at presentation; longer time to receive treatment; 
and presentation between December and May were all associated with increased risk of CAA. Additional factors 
associated with the presence of CAA were lower albumin, and higher corticosteroid use in those with CAA (Table 
3).   
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Treatment with IVIG and aspirin 
Excluding the 2 cases diagnosed after death, and excluding the 20 cases with incomplete data, 502/531 received 
IVIG (95%), with the recommended dose of 2g/kg (97%). 29/531 (5%) did not receive IVIG: 20 with complete KD; 
0 with incomplete KD; and 8 with atypical KD, (one not classified). The usual reason for not giving IVIG was 
delayed diagnosis, but in one case the parents refused therapy (Table 3). Anti-inflammatory dose aspirin (30-50 
mg/kg/day, divided into four daily doses) was given to 472/537; 41 did not receive any aspirin; data regarding 
aspirin were missing for the other cases. Following this, an anti-platelet dose of aspirin (3-5mg/kg once a day) 
was given to 460 (83%) children. As shown in Table 4, the proportion of patients with CAA was lowest in those 
treated with IVIG within 7 days of onset and increased progressively in the group treated between 7 and 10 days 
and above 10 days.  
 
Adjunctive therapy 
Overall, corticosteroids were used in 49/512 (10%) cases where CAA status was documented, either as primary 
adjunctive (4.6%), or as late rescue therapy (4.8%) (Table 3). Infliximab was given to 10/551 cases (1.8%). Many 
children were commenced on antimicrobials (n=73) before the diagnosis of KD was made. No other treatments 
were reported. 
 
Other outcomes  
Of the 523 cases with echocardiography performed within 30 days of diagnosis, data on follow up 
echocardiography beyond 30 days were available in 49/523 of which 40/49 had persistent CAA. Overall, 8/49 had 
persistent giant CAA, including the 4 cases of giant CAA under the age of 1 year. Three had arthralgia, one had 
anaemia, one had hypertension, and one had lethargy. In addition to the 2 cases who were diagnosed after death, 
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a third child with pre-existing neurological disease died from intractable seizures, providing an all-cause mortality 
rate of 3/553 (0.54%), and mortality directly attributable to KD of 2/553 (0.36%). 
 
 
DISCUSSION 
This prospective UK population-based study shows that the incidence of KD as reported by paediatricians in the 
UK and Ireland has risen since the last survey in 1990 (from 3.4 to 4.55/100,000 children under 5 years, with 
male: female ratio of 1.51:1. It is noteworthy that estimates of KD incidence based on hospital admission or GP 
database statistics previously reported more than double the number of cases in our survey 8 26. This BPSU 
survey used rigorous diagnostic criteria to ensure accurate case inclusion. In contrast hospital admission data are 
not based on strict epidemiological KD case definitions, usually relying on diagnoses assigned by junior doctors 
or coding clerks and are thus likely to significantly over-record KD cases. Conversely, the voluntary reporting 
system used by the BPSU could under-record cases, as busy paediatricians may not respond or recall all the 
cases or may believe their colleagues are doing the reporting.  Therefore, our BPSU data are likely to provide a 
minimum estimate of annual incidence. Many features observed in this UK and Ireland study are also seen in 
studies from other countries, including the majority of cases being less than 5 years old, seasonal occurrence with 
more cases in winter and spring, and increased proportion of Chinese or Japanese Asians and Black Africans 
relative to their proportion in the general population. We found an increased proportion of cases lived in rural 
areas relative to the population distribution. Early (within 30 days) all-cardiac complication rates for this unselected 
treated UK population were 28%; 19% had CAA at 6 weeks, based on a coronary Z score ≥2.5 (Table 2). 
Worryingly, 39% of KD patients under 1 year of age developed CAA despite IVIG; and mortality rates at 0.36% 
were approximately 10-fold lower than the last BPSU study.  
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We were surprised that residence in urban areas was associated with lower incidence of KD than rural residence. 
There might be many different explanations for this finding, including greater exposure to toxins used in farming, 
agriculture associated microorganisms, or increased exposure to pollens 3. The suggestion that wind patterns 
could propagate triggers might be of relevance in this context 6. 
There was a change in the case ascertainment protocol from the first year of the study to the second. We were 
obliged by the BPSU reporting restrictions to have a small number of cases (less than 300 in each year) and there 
was concern that including all cases of KD would make the total number too large. However, it was clear, during 
the first year of study, that we were being notified of incomplete cases and that we were not going to exceed 300 
cases per year. In addition, there was a new guideline that was published during the time of the study advising 
steroids in high risk cases. We wished to capture both of these pieces of information. Clearly, the incidence of all 
cases of KD could therefore only be based on the second year of study. Despite this, we saw little difference in 
the demographics between the two years. 
We found that the frequency of CAA (19%), is lower than the 29% observed in the treated cases in the original 
1990 BPSU study27, but significantly higher than CAA rates previously reported from other countries23 and 
comparable to reported coronary sequelae rates for untreated cases 1 17. This adds weight to our belief that the 
rise in observed incidence is not due to better case ascertainment, but due to a real increase in number of cases 
and also case severity. Similarly high CAA rates have now also been observed in Sweden 28 and Russia 29 with 
delayed diagnosis cited as a likely explanation for high coronary complication rates in the latter study. We found 
that the proportion with CAA was lowest in patients treated within 7 days, and this increased with later treatment.  
Our data therefore strongly suggest that delayed diagnosis and treatment is a significant factor contributing to the 
high incidence of CAA in the UK. Furthermore, the low numbers of patients receiving adjunctive treatments such 
as corticosteroids or anti-TNF, which are associated with  more rapid resolution of inflammation and reduced CAA 
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risk, suggests many UK KD patients are not receiving optimal therapy advised in national and international 
guidance 1. 
 
Our study confirms that children under 1 year are more likely to have atypical KD and higher rates of coronary 
sequelae (39%), as reported in other series 1. Diagnosis of KD is difficult in the absence of all the typical features. 
As a high proportion of infants under 1 year of age do not fulfil the KD diagnostic criteria, there is a need for 
increased awareness of the possibility of KD in any infant with evidence of persistent inflammation (raised CRP, 
ESR or white cell count) and no response to antibiotics. In these infants, echocardiography is an urgent 
investigation required as part of the diagnostic work up of suspected incomplete KD. A high index of suspicion is 
thus required, and early treatment with IVIG and additional anti-inflammatory agents, and referral to specialist 
units for suspected atypical KD cases in view of the high risk of CAA is advised. Our findings also support the 
previous suggestion that children under 1-year should be regarded as high risk for coronary sequelae 1, and 
therefore be targeted for more aggressive primary treatment. It is also of note that there was a higher rate of CAA 
in children in the second half of the study, after 1.2.2014. The most likely reason for this is that we included 
atypical KD in the second half of the study, which have CAA by definition. 
 
Ninety-four % of children received IVIG in line with current guidance along with high dose aspirin in almost all, 
although as previously highlighted, those children with CAA+ were treated later (median 10 days) than those 
without CAA (7 days), highlighting the importance of instituting treatment as early as possible (i.e. not just within 
10 days) to improve outcomes 30.   
 
Corticosteroids were only used in 10% of cases (Table 3); 4.6% of cases as primary therapy, and as rescue 
therapy in 4.8%. This overall relatively low use of corticosteroids, combined with delay in initiating treatment, could 
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explain the high CAA rates we observed since a recent meta-analysis of 2746 patients has now demonstrated 
that early addition of corticosteroids is associated with reduced risk of CAA compared with IVIG therapy alone, 
particularly for high risk cases (odds ratio 0.424; 95%CI, 0.270-0.665) 30. Arguably, however, all UK KD patients 
could be deemed “high-risk”, since 19% developed CAA within 30 days despite IVIG treatment, with even higher 
risk for children under the age of 1 year, of whom 39% developed CAA, of which 5% had giant CAA with poor 
prognostic outcomes. We would have liked to have had follow-up on the CAA after 30 days, but we were obliged 
by our protocol approval by the BPSU and National Information Governance, to keep this within the acute phase. 
We hope to be able to return to these patients and obtain ethical approval and consent for a follow-up study in 
the future. 
 
Limitations. 
BPSU methodology relies on busy doctors to complete data entry, and thus a surveillance-based study of this 
nature is limited since it is entirely dependent on the entry of data and case ascertainment for completeness. 
Therefore, although ours was a prospective study, it is expected that there will be a small proportion of cases that 
are not reported as evidenced in a recent German study suggesting that up to 44% of cases can be missed 31. 
This will only serve to increase the incidence of KD above that in the present reported study. Also, by the nature 
of BPSU study methodology, follow up data examining late cardiac sequelae are limited. 
 
CONCLUSIONS 
KD has a rising incidence in the UK and Ireland, and cardiac sequelae are higher than reported for other countries 
despite most patients receiving IVIG therapy. Treatment delay is likely to have been contributory to high CAA 
rates. A future National UK comparative clinical trial of corticosteroids as primary adjunctive therapy for unselected 
KD patients is now planned. In the meantime, general practitioners and paediatricians should be aware that 
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treatment to completely ablate systemic inflammation as early as possible is required to prevent lifelong cardiac 
sequelae, and that the historic KD therapeutic adage of “treatment within 10 days” is no longer fit for purpose.    
 
WHAT IS ALREADY KNOWN ON THIS TOPIC 
1. Kawasaki Disease is the commonest acquired heart disease in the western world, with highest incidence in 
North East Asians and with unknown aetiology. 
2.  Seasonal variation, with peaks in winter and spring, and reported epidemics suggest that there are 
environmental factors, which trigger the condition.   
3. The original BPSU study in 1990 suggested that UK patients might have high CAA rates despite IVIG. 
 
WHAT THIS STUDY ADDS 
1. There is a rising incidence of KD compared to 1990, with increased incidence in Chinese and Japanese Asians, 
and in children of Black African descent; and increased incidence in rural populations. 
2. Children under 1 year are at highest risk of CAA (39%) and are more likely to present with atypical KD.  
3. The overall frequency of CAA remains high at 19% despite more widespread use of IVIG, although mortality is 
now 10-fold lower than documented in 1990. Late diagnosis and treatment is associated with coronary artery 
aneurysms.  
 
 
Authorship contribution 
 
RT, AH, RMW, PB and RL designed the project. Cases were assessed by the expert panel review (RT, RMW, 
AR, JT, DS, PB) and PC collected and recorded the data. SD provided patient participation support and 
informed families involved in the study of ongoing progress. CM, AH and OF provided local support and 
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assisted with recruitment. RMW, RS and MD undertook statistical analysis. All authors satisfied the 
contributorship requirements.   
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Figure legends 
 
Figure 1. Incidence of KD by month at diagnosis, showing breakdown into complete, atypical and incomplete 
cases. PM was diagnosis at post-mortem.  
 
Figure 2. Plot of urbanicity (as assessed by population per postcode, per sq km) against number of cases of 
KD. 
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Table 1. The demographics of Kawasaki disease in the UK and Ireland. 
 
 
  
 
Complete Atypical Incomplete 
Post-
mortem 
Total 
Total No 
of cases 
 
389  % 46 %  116 %  2 %  553 100% 
Sex Male 231 60% 28 61% 64 55% 0   323 59% 
 Female 153 40% 18 39% 42 36% 2 100% 215 39% 
 Sex unreported 5 1% 0 0% 10 9% 0   15 3% 
 Male:Female ratio 1.50:1   1.56:1   1.52:1   0   1.51:1   
Age 
(years) 
<1 
50 13% 20 43% 25 22% 2 100% 97 18% 
 1-4 251 64% 19 41% 48 41% 0   318 57% 
 5-9 69 18% 5 11% 28 24% 0   102 18% 
 10-16 7 2% 1 2% 1 1% 0   9 2% 
  Not reported 12 3% 1 2% 14 12% 0   27 5% 
Ethnicity White 257 75% 26 70% 71 72% 1 50% 355 64% 
 White & Black 12 6% 4 5% 4 2% 0   20 7% 
 White & Asian 10 2% 1 2% 3 0% 0   14 2% 
 Black 39 3% 4 6% 3 0% 0   46 4% 
 Asian sub-continent 25 7% 5 8% 12 9% 0   42 10% 
 Other Asian  11 5% 1 8% 3 7% 1 50%  16 8% 
 Chinese/Japanese 14 3% 4 2% 2 9% 0   20 5% 
 Others 21 5% 1 2% 18 16% 0  40 7% 
Country  Scotland 19 5% 3 7% 7 6% 0   28 5% 
 Republic of Ireland 23 6% 0 0% 9 8% 0   31 6% 
 Wales 24 6% 7 15% 6 5% 0   35 6% 
 N. Ireland 9 2% 0 0% 2 2% 0   12 2% 
 IoM/Channel Islands 2 1% 2 4% 1 1% 0  5 1% 
 England 312 80% 34 74% 94 79% 2 100% 442 80% 
Date of 
illness 
1.2.13-31.1.14 
186 49% 13 28% 27 25% 0   226 42% 
 1.2.14-31.1.15 161 42% 30 65% 70 60% 2 100% 263 49% 
 Outside study period 36 9% 3 7% 9 8% 0   48 9% 
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Table 2. Echocardiographic data showing Cardiac complications. There were 11 children in whom the weights 
and z scores were missing, which have not been included in the table. 
Time of 
Echo 
Number 
assessed 
Coronary
z<2 
Coronary
2≤z<2.5 
Coronary 
2.5≤z<5 
Coronary 
5≤z<10 
Coronary 
z≥10 
Pericardial 
Effusion 
Valve 
regurgitation 
At Diagnosis 523 389 28 59 28 8 25 7 
>30 days 49  9 20 12 8 0 0 
 
 
Table 3:  Association of coronary artery status with individual variables. CAA+ = those with coronary artery 
aneurysms. CAA- = those without aneurysms. IVIG = intravenous immunoglobulin. P value is difference in 
median: ns = not significant. The numbers of patients receiving corticosteroids were too small for meaningful 
statistical testing. There were 11 children in whom the weights and z scores were missing, which have not been 
included in the table.  
Criterion CAA+ (n=95) CAA- (n=417) P value 
Male 62 (69%) 247 (59%) 0.27 ns 
Median lowest Albumin g/L 
Range 
26 
(13, 41) n=83 
31 
(21, 49) n=372 
0.049 
Median Lowest Sodium mmol/L 
Range 
134 
(125, 142) n=48 
134 
(123, 141) n=210 
0.92 ns 
Median Lowest Platelet count x109/L 
Range 
212 
(30, 442) n=95 
245 
(54, 450) n=415 
0.15 ns 
Median Age months at presentation 
Range 
21.6 
(2.4, 190.0) n=93 
36.0 
(1.2, 190.0) n=409 
0.005 
Median Time to treatment (days) 
Range 
10.0 
(2, 37) 
7.0 
(1, 36) 
0.005 
Mucosal involvement at diagnosis 77/95 (81%) 360/416 (87%) 0.19 ns 
Dec-May presentation 64/95 (67%) 245/416 (59%) 0.12 ns 
Presentation before 1.2.2014 53/95 (56%) 210/416 (50%) 0.35 ns 
Primary steroid use 11/95 (12%) 13 (3%)  
Late corticosteroid use 13 (14%) 12 (3%)  
No corticosteroid use 67/92 (73%) 359/384 (93%) 0.03 
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Table 4: Association of time of treatment with Intravenous immunoglobulin (IVIG) with coronary artery aneurysms. 
Numbers were small, so statistical comparison of these groups was not performed. Absolute numbers with % in 
brackets 
  
Age <1 year Age >1 year 
IVIG timing Number 
of cases 
Z<2.5 Z≥2.5 
  
missing cases Z<2.5 Z≥2.5 missing 
IVIG before day 7 45 33 11 1 160 138 17 5 
IVIG day 7-10 28 12 15 1 142 116 23 3 
IVIG>day 10 14 3 9 2 79 62 15 2 
No IVIG or missing 8 4 2   49 41 1   
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